GlassScriptPhysician profile
Craig Luetkemeyer
NPI 1013279967
$1,428.23
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $80.19 · 2021: $122 · 2022: $323 · 2023: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.18 | 2021-2023 | |
| Novo Nordisk INC | $274.72 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $160.99 | 2019-2023 | Mounjaro |
| Amgen INC. | $104.27 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $88.57 | 2019-2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $81.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $60.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $55.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.18 | 2022-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $34.17 | 2022 | |
| Astellas Pharma US INC | $28.58 | 2023 | Veozah |
| Pfizer INC. | $24.76 | 2019-2023 | |
| Allergan, INC. | $21.66 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.70 | 2019 | |
| Abbott Laboratories | $18.53 | 2023 | Freestyle Libre 2 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.99 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.54 | 2023 | Xarelto |
| Exact Sciences Corporation | $13.38 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $12.88 | 2019 | |
| Daiichi Sankyo INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Luetkemeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.